Abstract
Serum uric acid (SUA) is considered as a marker of nature progression of chronic heart failure (CHF) mediated cardiovascular remodeling. Progression of CHF associates with declining of circulating endothelial progenitor cells (EPCs) in the peripheral circulation. t he objective of this study: to establish predictive relationship between the content of uric acid in the blood and the level of circulating endothelial progenitor cells in patients with CHF of ischemic origin. Methods: The study population was structured retrospectively in 126 subjects (54 male), aged 48 to 62 years, with mild-to-severe ischemic CHFSUA level was measured by enzymatic methods, NT-pro-BNP level was examined by immunoelectrochemiluminesence method. EPCs were determined as CD 34 + cells by the flowcytometric technique using High-Definition Fluorescence Activated Cell Sorter methodology. All biomarkers were measured at baseline. The study was approved by an institutional review committee. Results: Concentrations of SUA were distributed by quartiles (Me; IQR): QI=201,1 (190,6; 223,3) umol/l; QII=275,3 (232,0; 311,0) umol/l; QIII=358,0 (320,0; 390,0) mmol/l; and QIV=449,0 (400,0; 496,0) umol/l. We found an independent impact of SUA on counts of CD14 + CD309 + EPCs (r=-0.388; P=0.001) and CD14 + CD309 + Tie2 + MPCs (r=-0.414; P=0.001), but on CD45 + CD34 + EPCs (r=-0.214; P=0.22) and CD45 - CD34 + MPCs (r=-0.16; P=0.16) did not. Cox proportional adjusted Odds Ratios analyses for CD14 + CD309 + and CD14 + CD309 + Tie2 + EPCs by SUA Quartiles (Q) has showed that high Q (Q3 and Q4) of SUA versus low Q (Q1 and Q2) associated with increased risk of depletion of both CD14 + CD309 + and CD14 + CD309 + Tie2 + EPCs. The ROC analysis showed that there was the cut-off point for the SUA level with the best prognostic potential on the risk of decreasing EPCs in both models equal 315,0 umol/l. Conclusion: Circulating level of proangiogenic EPCs phenotyped as CD14 + CD309 + and CD14 + CD309 + Tie2 + is declined progressively depended on quartiles of SUA level in CHF subjects.
Highlights
Цель работы – установить прогностическую взаимосвязь между содержанием мочевой кислоты в крови и уровнем циркулирующих эндотелиальных прогениторных клеток у пациентов с хронічної серцевої недостатності (ХСН) ишемического генеза
The study population was structured retrospectively in 126 subjects (54 male), aged 48 to 62 years, with mild-tosevere ischemic CHFSUA level was measured by enzymatic methods, NT-pro-BNP level was examined by immunoelectrochemiluminesence method
endothelial progenitor cells (EPCs) were determined as CD 34+ cells by the flowcytometric technique using High-Definition Fluorescence Activated Cell Sorter methodology
Summary
Мочевая кислота сыворотки крови считается маркером прогрессирования хронической сердечной недостаточности (ХСН), связанной с сердечно-сосудистым ремоделированием. Установлена ассоциация мочевой кислоты в крови с количеством ЭПК с фенотипами CD14+CD309+ (r = -0,388; P = 0,001) и CD14+CD309+Tie2+ (r = -0,414; P = 0,001). Циркулирующий уровень проангиогенных ЭПК с фенотипами CD14+CD309+ и CD14+CD309+Tie2+ у пациентов с ХСН снижается пропорционально повышению концентрации мочевой кислоты в крови. Встановлена асоціація сечової кислоти у крові з кількістю ЕПК із фенотипами CD14+CD309+ (r = -0,388; P = 0,001) і CD14+CD309+Tie2+ (r = -0,414; P = 0.001). При цьому точка поділу концентрації сечової кислоти з оптимальним співвідношенням чутливості та специфічності щодо зниження ЕПК із фенотипами CD14+CD309+ і CD14+CD309+Tie2+ становить 315,0 мкмоль/л. Циркулюючий рівень проангіогенних ЕПК із фенотипами CD14+CD309+ і CD14+CD309+Tie2+ у пацієнтів із ХСН знижується пропорційно підвищенню концентрації сечової кислоти у крові. The objective of this study: to establish predictive relationship between the content of uric acid in the blood and the level of circulating endothelial progenitor cells in patients with CHF of ischemic origin
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
